Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672305 | 0.82 | MTNR1B (0.47) | ALOX5PTGS1PTGS2SPRGAA | |
| SCHEMBL5985874 | 0.79 | KDM4E (0.41) | BCHEACHEPOLB | |
| SCHEMBL930733 | 0.76 | PRKCI (0.46) | LMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL2382103 | 0.76 | PDK1 (0.40) | — | |
| SCHEMBL27377243 | 0.76 | ALDH1A1 (0.39) | — | |
| SCHEMBL2112606 | 0.76 | KDM4E (0.59) | POLB | |
| SCHEMBL31035937 | 0.76 | PRKCI (0.46) | LMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL8295560 | 0.76 | KMT2A (0.47) | LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL12523498 | 0.76 | GSK3B (0.40) | MTNR1BMTNR1A | |
| SCHEMBL13886016 | 0.76 | CHRNA7 (0.42) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271658-A1 | TRICYCLIC KRAS INHIBITORS | ERASCA, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022266069-A1 | TRICYCLIC KRAS G12D INHIBITORS | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-8691864-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | HORIZON THERAPEUTICS USA, INC. (SUCCESSOR IN INTEREST TO RAPTOR PHARMACEUTICAL CORP.) | 2014-04-08 | — | — | US | disclosed |
| US-20120295946-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | National Institute of Health (NIH) | 2012-11-22 | — | — | US | disclosed |
| US-8258172-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | RAPTOR PHARMACEUTICAL CORP (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110021594-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | Raptor Pharmaceutical Corp. | 2011-01-27 | — | — | US | disclosed |
| US-7786162-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | Raptor Pharmaceutical Corp. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090131501-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | TORREYPINES THERAPEUTICS (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1349858-B1 | AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF | US GOV HEALTH & HUMAN SERV (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7153882-B2 | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060270729-A1 | Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof | GREIG NIGEL H | 2006-11-30 | — | — | US | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| US-20040138282-A1 | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof | HORIZON THERAPEUTICS USA, INC. (SUCCESSOR IN INTEREST TO RAPTOR PHARMACEUTICAL CORP.) | 2004-07-15 | — | — | US | disclosed |
| EP-1349858-A2 | AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002048150-A2 | AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021594-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | ALOX5 893/4885PTGS1 1504/4885PTGS2 2052/4885 |
| US-20090131501-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | ALOX5 893/4885PTGS1 1504/4885PTGS2 2052/4885 |
| US-20060270729-A1 | Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof | IAPP, APP, BACE1 | ALOX5 1105/4885PTGS1 2666/4885PTGS2 2948/4885 |
| US-20120295946-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | ALOX5 893/4885PTGS1 1504/4885PTGS2 2052/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | ALOX5 659/4885PTGS1 653/4885PTGS2 391/4885 |
| US-20040138282-A1 | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof | APP, BACE1, CTH | ALOX5 551/4885PTGS1 1213/4885PTGS2 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.